Advertisement

Topics

Seqirus Company Profile

13:18 EDT 15th August 2018 | BioPortfolio

In an industry first, Seqirus has successfully produced cell-based influenza vaccine at commercial scale using a candidate vaccine virus (CVV) that has been isolated and grown in cells, rather than in eggs.1,2 CVVs are prepared by the World Health Organization (WHO) Global Influenza Surveillance and Response System (GISRS) and associated laboratories, and are used by manufacturers to develop and produce influenza vaccines.


News Articles [8 Associated News Articles listed on BioPortfolio]

Seqirus files for European approval for QIVc

UK-headquartered Seqirus today announced its intention to commercialize its cell-based quadrivalent flu…

Human Vaccines Project and Seqirus collaborate to accelerate universal flu vaccine research

The Human Vaccines Project, a nonprofit public-private partnership focused on decoding the immune system to improve human health, and Seqirus, a global leader in the prevention of influenza, announced...

Human Vaccines Project and Seqirus partner to advance universal flu vaccine research

(Human Vaccines Project) The Human Vaccines Project, a nonprofit public-private partnership focused on decoding the immune system to improve human health, announced today that Seqirus, a global leader...

Seqirus to join universal flu vaccine initiative

Manufacturer of egg-based influenza vaccines in the UK, Seqirus, has revealed it is joining the Human Vaccines Project’s Universal Influenza Vaccine Initiative (UIVI) — a collaborative effort to a...

Major UK investment to boost influenza vaccine production, jobs and exports

Nearly a hundred new high tech jobs are to be created at the Liverpool manufacturing site of Seqirus, one of the world’s largest influenza vaccine companies, as a result of major new investment....

Seqirus begins shipping 2018-2019 influenza vaccines

Seqirus to Launch Adjuvanted Influenza Vaccine in the UK

The launch of FLUAD® in UK represents an exciting milestone for Seqirus.  As the only global vaccine company solely dedicated to influenza, Seqirus are proud to help meet the significant heal...

The 14th Bionow Annual Awards successfully showcases the best of the northern life sciences sector

Bionow, is delighted to announce the winners of the 2015 Bionow Annual Awards, the ceremony for which took place at the Mere Golf Resort and Spa, Cheshire, on the 26th November 2015. The prestigious ...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.

This is a study to assess the immune (antibody) response and safety of a Seqirus split virion, inactivated Quadrivalent Influenza Vaccine (Seqirus QIV), in comparison with a US licensed 20...

Companies [1 Associated Companies listed on BioPortfolio]

Seqirus

In an industry first, Seqirus has successfully produced cell-based influenza vaccine at commercial scale using a candidate vaccine virus (CVV) that has been isolated and grown in ...

More Information about "Seqirus" on BioPortfolio

We have published hundreds of Seqirus news stories on BioPortfolio along with dozens of Seqirus Clinical Trials and PubMed Articles about Seqirus for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Seqirus Companies in our database. You can also find out about relevant Seqirus Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Influenza
Influenza or 'flu' is a respiratory illness associated with infection by influenza virus. Symptoms frequently include headache, fever, cough, sore throat, aching muscles and joints. There is a wide spectrum of severity of illness ranging from min...


Corporate Database Quicklinks



Searches Linking to this Company Record